Skip to main content
MyDeficiencies

Canagliflozin

SGLT2 Inhibitor

Also sold as Invokana.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Canagliflozin has no classical drug-nutrient depletion mechanism in the chelation/malabsorption/enzyme-induction sense. It is mainly cleared by UGT1A9/UGT2B4 glucuronidation, does not induce CYP450 enzymes, and is minimally excreted unchanged in urine (under 1%). Its nutrient-relevant activity instead runs through its intended mechanism: blocking SGLT2-mediated glucose reabsorption in the proximal renal tubule, which increases glucosuria, mildly increases distal sodium delivery, and shifts several downstream renal and metabolic parameters. The real, drug-specific signals found in the literature are almost all retention or shift effects, not depletion : serum magnesium rises (not falls), serum potassium can rise in renal impairment (not fall), serum phosphate rises transiently, hemoglobin and hematocrit rise, and the body shifts toward ketone body and fatty-acid fuel use. The one axis that moves in a depletion-like direction is bone-mineral signaling: canagliflozin acutely suppresses active vitamin D (1,25-dihydroxyvitamin D) and raises FGF23 and PTH, an effect that is larger in people who are already vitamin D deficient and blunted by vitamin D repletion, and this tracks with the drug's own labeled bone-fracture warning.

SGLT2 inhibitor · ATC A10BK02 · also sold as Invokana and Invokamet and Invokamet XR · reviewed 2026-09-20. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Canagliflozin in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: ≥2 independent Tier A sources, this drug in the studied cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, low frequency, or a functional (not deficiency-level) shift.
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence to support even a yellow grade, and no circulating claim to rebut as white. A disclosed absence of evidence (or of accessible evidence), never reworded as reassurance.

What the research found

Vitamin D

Orange — Moderate

See study details

Canagliflozin acutely lowers circulating active vitamin D and raises PTH and FGF23; the effect is markedly larger in people who start out vitamin D deficient and is blunted by vitamin D repletion.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, low frequency, or a functional (not deficiency-level) shift. orange

Limits on what this shows

  • Key negative/null findings: Both studies were short (5-day) exposures in healthy or non-diabetic volunteers, not chronic canagliflozin users with type 2 diabetes; whether the acute PTH/1,25(OH)2D shift persists or attenuates over years of therapy in the treated T2DM population is not established by these two studies. A separate 2-year T2DM bone-metabolism study found only minimal, within-normal-limits mineral changes on chronic dosing.
  • At-risk subgroups: People with baseline vitamin D deficiency (25(OH)D <20 ng/mL); people already at elevated fracture risk.
  • Counter-evidence on record: Vitamin D3 repletion to sufficiency (25(OH)D ≥30 ng/mL) significantly blunted both the 1,25(OH)2D and PTH response in the same cohort, which is itself evidence the effect is real and modifiable, not an artifact.

Regulatory status

Not a named warning in the FDA label under this mechanism, but the label's separate bone-fracture warning (Section 5.7, "increased risk of bone fracture, occurring as early as 12 weeks") is consistent with this axis being active in humans.

Population evidence

(1) Randomized, single-blind, placebo-controlled crossover study, NIH Clinical Center, 25 healthy adult volunteers (canagliflozin 300 mg/day x5 days vs placebo): 1,25(OH)2D fell a maximum of 9.4% ± 1.5% at 48 hours (P<0.0001); PTH rose ~25% by day 5 (P<0.0001); FGF23 rose 20% (AUC 3,855 vs 3,204 pg/mL x 48h, P<0.0001). (2) Paired crossover study in 11 Old Order Amish adults with baseline 25(OH)D ≤20 ng/mL (canagliflozin 300 mg/day x5 days, tested before and after vitamin D3 repletion to 25(OH)D ≥30 ng/mL): while deficient, 1,25(OH)2D fell 31.3% ± 4.7% (P=.0003) and PTH rose 36.2% ± 6.2% (P=.0009); after repletion, the falls/rises were far smaller (1,25(OH)2D -9.3% ± 8.3%, P=.3; PTH +9.7% ± 3.7%, P=.02), with the protective effect of repletion itself significant (P=.04 and P=.005 respectively).

Mechanism

Named: canagliflozin triggers an FGF23-driven suppression of renal 1-alpha-hydroxylase, lowering 1,25(OH)2D synthesis and secondarily raising PTH; the effect is amplified when baseline vitamin D stores are already low.

Counter-evidence held on record

This is evidence for maintaining vitamin D sufficiency during canagliflozin therapy, not evidence that canagliflozin causes vitamin D deficiency on its own. Any supplementation decision should be based on a measured 25(OH)D level and a clinician's judgment, not on this finding alone.

Magnesium

Orange — Moderate

See study details

Canagliflozin raises serum magnesium; this is a retention effect, the reverse of a "diuretic wastes magnesium" assumption, and stays within the normal range for most patients.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, low frequency, or a functional (not deficiency-level) shift. orange

Limits on what this shows

  • Key negative/null findings: Same 18-trial meta-analysis found no significant change in serum calcium or potassium at the whole-population level (see Calcium, Fails verification, and the bounded Potassium entry below).
  • At-risk subgroups: Patients with renal impairment or those on other magnesium-elevating drugs were not specifically flagged for hypermagnesemia risk in the cited data; no hypermagnesemia adverse-event signal was reported in either source.
  • Counter-evidence on record: "Baseline and post-randomization serum Mg levels are not associated with cardiovascular outcomes" in the CANVAS analysis — the change is real but was not shown to drive clinical benefit or harm on its own.

Regulatory status

Listed in prescribing information as a common (1-10% incidence) laboratory finding: "increased serum magnesium."

Population evidence

(1) Post hoc analysis of pooled CANVAS/CANVAS-R data, 10,140 T2DM patients (5,794 canagliflozin, 4,346 placebo), high cardiovascular risk: mean canagliflozin-vs-placebo difference in serum magnesium 0.07 mmol/L (95% CI 0.065-0.072, P<.001), sustained through follow-up; by week 6, canagliflozin group 0.86 ± 0.09 mmol/L vs placebo 0.78 ± 0.09 mmol/L (baseline ~0.77 mmol/L both groups). (2) Meta-analysis of 18 RCTs, 15,309 patients, including canagliflozin, dapagliflozin, empagliflozin, and ipragliflozin: canagliflozin-specific weighted mean difference +0.06 mmol/L (100 mg) and +0.09 mmol/L (300 mg) vs placebo, both statistically significant, described by the authors as a class effect.

Mechanism

Named, though not directly confirmed by a canagliflozin-specific mechanistic study: chronic hyperglycemia itself causes glycosuria-associated osmotic magnesium wasting; by lowering glucose via SGLT2 inhibition, canagliflozin is proposed to reverse this baseline diabetic magnesium loss, and class-level literature also proposes upregulated distal tubular magnesium reabsorption.

Counter-evidence held on record

This is a retention/increase finding, not a deficiency. It does not support magnesium supplementation, and stacking canagliflozin with other magnesium-elevating drugs or supplements in a patient with renal impairment could theoretically raise hypermagnesemia risk, though this has not been directly documented.

Potassium

Orange — Moderate

See study details

Canagliflozin can raise serum potassium in patients with renal impairment; this is a retention risk, not a depletion risk, and is not shown as a general population effect.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, low frequency, or a functional (not deficiency-level) shift. orange

Limits on what this shows

  • Key negative/null findings: No significant potassium change in the general (non-renally-impaired) trial population per the class-level meta-analysis.
  • At-risk subgroups: Moderate-to-severe renal impairment; concurrent use of ACE inhibitors, ARBs, potassium-sparing diuretics, or potassium supplements.
  • Counter-evidence on record: Class-level null finding for potassium in the broader, less renally-impaired trial population (see above), supporting that this is a bounded, subgroup-specific effect rather than a universal one.

Regulatory status

FDA label, renal impairment sub-study data: increases in serum potassium to >5.4 mEq/L and ≥15% above baseline occurred in 5.3% (placebo), 5.0% (100 mg), and 8.8% (300 mg) of patients with moderate renal impairment.

Population evidence

Randomized, placebo-controlled sub-study in patients with moderate renal impairment (Tier A, drug label). By contrast, the 18-trial, 15,309-patient SGLT2 inhibitor meta-analysis found no significant change in serum potassium across trials at the whole-population level (most participants had preserved or only mildly reduced renal function).

Mechanism

Named: SGLT2 inhibition raises distal tubular sodium delivery and engages tubuloglomerular feedback, reducing glomerular filtration acutely; in patients with reduced baseline renal reserve, this transient GFR reduction and associated hemodynamic change can impair potassium excretion.

Counter-evidence held on record

This is a retention risk in a defined subgroup, not a depletion risk. Potassium supplementation is not indicated by this finding in anyone, and clinicians should monitor serum potassium more closely at initiation and dose changes in patients with renal impairment, per the label.

Phosphate

Orange — Moderate

See study details

Canagliflozin transiently raises serum phosphate acutely; chronic dosing data show only minimal, within-normal-limits change.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, low frequency, or a functional (not deficiency-level) shift. orange

Limits on what this shows

  • Key negative/null findings: Chronic 2-year dosing data show the phosphate change stays within normal limits, a materially smaller signal than the acute 16% rise.
  • At-risk subgroups: Not specifically identified beyond the bone-mineral axis populations noted under Vitamin D.
  • Counter-evidence on record: The attenuation from acute (16%) to chronic ("minimal, within normal limits") is itself a form of null/attenuating evidence, arguing against a clinically important sustained phosphate excess.

Regulatory status

Listed as a common (1-10%) laboratory finding: "increased serum phosphate."

Population evidence

(1) The same 25-healthy-volunteer, 5-day RCT crossover cited under Vitamin D: serum phosphorus rose 16% acutely (maximum difference 0.61 mg/dL at 36 hours). (2) A 2-year T2DM bone/mineral-metabolism study of canagliflozin 100 mg and 300 mg (Bilezikian et al.) reported only minimal increases in serum phosphate and magnesium, within normal limits, alongside increased bone turnover markers (beta-CTX and osteocalcin both rose) and a small hip BMD decline (-0.9% to -1.2% vs placebo at 2 years, associated with weight loss).

Mechanism

Not fully elucidated; partially paradoxical, since the concurrent FGF23 rise would conventionally be expected to drive phosphate down via renal phosphate wasting. Proposed explanation: transient hemoconcentration from osmotic diuresis and incomplete renal counter-regulation in the acute setting, attenuating with chronic dosing as PTH/FGF23 compensation catches up.

Counter-evidence held on record

This is a mineral-handling shift tied to the same bone-mineral axis as the vitamin D/PTH/FGF23 finding above, not a phosphate deficiency, and not an indication to restrict or supplement dietary phosphate.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

One canagliflozin-specific animal study found the drug promotes mitochondrial biogenesis in an acute kidney injury model, a protective rather than burdensome effect; no canagliflozin-specific evidence of mitochondrial harm was found.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. yellow

Limits on what this shows

  • Key negative/null findings: None identified; only a single study was found, so this is a low-confidence signal by count alone regardless of direction.
  • At-risk subgroups: Not established in humans; this is a rat AKI model, not a chronic human-use context.
  • Counter-evidence on record: None identified.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier B, animal (rat, glycerol-induced acute kidney injury model): canagliflozin promoted mitochondrial biogenesis via the AMPK/SIRT1/FOXO-3a/PGC-1α and Nrf2/HO-1 pathways (Bishr et al., 2021). This source was indexed as a preprint (SSRN Electronic Journal) at the time of this review; independent confirmation of subsequent peer-reviewed journal publication was not completed.

Mechanism

Named: AMPK/SIRT1/PGC-1α pathway activation, the same pathway family implicated in the Oxidative stress entry above (see Overlap map).

Counter-evidence held on record

This is a single animal study, not human data, and its preprint status was not independently resolved. It should not be read as established proof that canagliflozin protects human mitochondria, only as a mechanistic signal in the reverse (protective) direction from what "mitochondrial burden" concern typically implies.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

Multiple canagliflozin-specific animal and in vitro studies report reduced oxidative stress markers with treatment (a protective, reverse-direction finding), with one commentary flagging a tissue-specific caution about canagliflozin's off-target SGLT1 inhibition in heart muscle.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. yellow

Limits on what this shows

  • Key negative/null findings: A 2021 European Heart Journal editorial ("Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage," Schiattarella & Bode) raises a tissue-specific caution that canagliflozin's unique off-target SGLT1 inhibition (unlike more SGLT2-selective agents) may produce different, potentially adverse, myocardial oxidative-stress effects than its renal-protective profile suggests; this review could not retrieve the primary data this editorial comments on.
  • At-risk subgroups: Not established in humans.
  • Counter-evidence on record: The EHJ editorial noted above is the only source found complicating the otherwise consistent protective-direction animal data; it is a commentary, not primary data, so it is recorded as a caution rather than a contradicting Tier A/B finding.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier B, all animal or in vitro, all canagliflozin-specific: an isoprenaline-induced oxidative stress rat model showing canagliflozin reduced renal oxidative stress/inflammation via AMPK-Akt-eNOS signaling (Sci Rep 2020); an isoprenaline-induced cardiomyocyte oxidative stress model showing benefit via heme oxygenase-1 (Biotechnic & Histochemistry 2023); a diabetic nephropathy model showing reduced ER-stress/oxidative-stress crosstalk via Nrf2 (Diabetes Res Clin Pract 2023); an atherosclerosis model showing reduced oxidative stress/inflammation/autophagy markers (Cardiovasc Innov Appl 2024); and an in vitro comparison versus empagliflozin (Int J Pharma Bio Sci 2017).

Mechanism

Named: AMPK/SIRT1/Nrf2-HO-1 and related antioxidant-pathway activation, consistent across several of the animal models.

Counter-evidence held on record

None of this evidence is in humans, and none supports an antioxidant-supplement recommendation. A common depletion-content framing that canagliflozin "causes oxidative stress" is not supported by the animal/in vitro data found, which mostly point the opposite direction; see Fails verification is not invoked here only because no specific canagliflozin oxidative-stress-depletion claim was located to rebut directly (see access-note limitation on the circulating-claim sweep).

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron

Yellow — Low

See study details

Dapagliflozin and empagliflozin have documented effects on iron availability and redistribution in heart-failure trials; canagliflozin itself has not been studied for iron status, and canagliflozin's own trial program is in type 2 diabetes/chronic kidney disease populations, not the heart-failure populations where the class-level iron data exist.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. yellow

Limits on what this shows

  • Key negative/null findings: A dedicated Crossref search for canagliflozin plus iron or ferritin returned no drug-specific studies of any design.
  • At-risk subgroups: Not established for canagliflozin specifically.
  • Counter-evidence on record: None found; this is an absence-of-evidence situation for canagliflozin specifically, not a contradicted claim.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier C for canagliflozin: class-level literature (JACC: Heart Failure commentary, 2023, referencing DAPA-HF, EMPA-REG OUTCOME, and EMPEROR-Reduced) describes SGLT2 inhibitor-associated enhanced erythropoiesis and "adaptive iron redistribution" and discusses interactions between SGLT2 inhibitor therapy and intravenous iron in heart failure. Canagliflozin was confirmed absent from the cohorts underlying this commentary (dapagliflozin and empagliflozin only).

Mechanism

Proposed at the class level: enhanced erythropoiesis (see Oxygen delivery/utilization entry) increases iron utilization/mobilization from stores, which is plausible to extend to canagliflozin given its shared SGLT2 mechanism, but has not been directly tested for this drug.

Counter-evidence held on record

This is explicitly a class extrapolation, not canagliflozin-specific evidence. It should not be read as "canagliflozin depletes iron" or "canagliflozin fixes iron deficiency"; it means only that the mechanism class this drug belongs to has documented iron-related effects in other members, tested in a different patient population (heart failure) than canagliflozin's own approved/studied population.

Copper

Not graded — disclosed evidence gap

See study details

No canagliflozin-specific, class-level, or circulating claim evidence was found for copper in either direction.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Both conditions for ungraded are met: no Tier B or Tier C evidence exists (a dedicated Crossref API search for canagliflozin plus copper or ceruloplasmin returned no relevant results after review of all 8 returned items, none of which addressed copper metabolism, copper interactions, or ceruloplasmin), and no circulating consumer or practitioner claim about canagliflozin and copper was located to rebut as white. This is a genuine literature gap as far as this review's tooling could reach, not a finding of safety.

Tooling note

This session's general WebSearch budget was exhausted before the copper-specific sweep could be run through multiple consumer-facing search engines (search engines were also blocked by robots.txt for direct fetch), so the circulating-claim side of this check relied only on what surfaced incidentally through the drug-specific literature search (Crossref, PubMed, DailyMed). A future revision with full search access should re-run this check.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

Canagliflozin measurably alters gut (and oral and ocular surface) microbial composition in type 2 diabetes patients and shifts gut microbiota and related metabolites in diabetic mice; whether this represents a risk, a benefit, or a neutral shift is not established.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for reverse-direction/protective findings and context flags. yellow

Limits on what this shows

  • Key negative/null findings: None identified; the mouse-model taxa shifts reported (increased Muribaculum and Lachnospiraceae) are generally associated with favorable, not adverse, metabolic phenotypes in the broader microbiome literature, arguing against framing this as straightforward "risk."
  • At-risk subgroups: Not established.
  • Counter-evidence on record: None found; but the uncertain clinical direction (favorable-appearing taxa shifts in the animal data) argues against a "risk" framing pending human functional outcome data.

Regulatory status

Not addressed in the FDA label.

Population evidence

Human: a study titled "Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus" (PMID 37867512) confirms canagliflozin-specific compositional change in a T2DM cohort by its title and indexing; this review could not extract the full quantitative results (see access note below), so effect size and direction of clinical significance are not independently confirmed here. Animal: an 8-week gavage study in type 2 diabetic mice found canagliflozin increased GLP-1 and shifted gut microbiota composition (increased Muribaculum, Ruminococcaceae_UCG_014, Lachnospiraceae-UCG-001; decreased fecal ursodeoxycholic and hyodeoxycholic acid; increased fecal fatty-acid metabolites), affecting intestinal fatty-acid and bile-acid metabolism.

Mechanism

Proposed: glucosuria-altered luminal substrate availability, altered bile-acid signaling, and GLP-1-mediated changes in gut transit and secretions, each plausible but not directly demonstrated to cause a functional deficiency or dysbiosis-linked harm in this drug specifically.

Counter-evidence held on record

A real compositional change is documented, but this dossier cannot confirm it represents harm; it should be read as "canagliflozin measurably changes the gut microbiome," not as "canagliflozin damages the gut microbiome."

  • Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus. 2023. PMID 37867512. — Human, type 2 diabetes cohort, canagliflozin-specific, per title/indexing.Full text/abstract could not be extracted: PubMed's article page returned only an empty JavaScript shell to the fetch tool, and PMC/Europe PMC access was repeatedly rate-limited (429) or connection-rejected (403) throughout this session. Quantitative results (taxa, effect sizes) are not independently confirmed in this dossier; only the drug/population/finding-direction implied by the title is used.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Orange — Moderate

See study details

Canagliflozin raises hemoglobin and hematocrit in a dose-dependent way; this improves measured oxygen-carrying capacity for most patients rather than impairing it, with a minority crossing above the normal range.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, low frequency, or a functional (not deficiency-level) shift. orange

Limits on what this shows

  • Key negative/null findings: No canagliflozin-specific study was found directly quantifying how much of the hemoglobin rise is hemoconcentration versus true erythropoiesis; this split is documented for other SGLT2 inhibitors in the class-level literature, not confirmed drug-specifically here.
  • At-risk subgroups: Patients already at risk of polycythemia or thrombosis, and those on concurrent erythropoiesis-stimulating agents, are the group in whom the minority-range hemoglobin elevation is most relevant.
  • Counter-evidence on record: None found contradicting the direction; the effect is consistently upward (hemoglobin/hematocrit increase) across the cited program data.

Regulatory status

FDA label, pooled Phase 3 program data: mean hemoglobin change from baseline -0.18 g/dL (placebo), +0.47 g/dL (100 mg), +0.51 g/dL (300 mg). At end of treatment, 4.0% (100 mg) and 2.7% (300 mg) of patients had hemoglobin above the normal range, versus a much smaller placebo rate.

Population evidence

Tier A, direct measurement from the canagliflozin registration trial program (drug label). Class-level mechanistic literature (not canagliflozin-specific) proposes that SGLT2 inhibitors enhance renal and hepatic erythropoietin synthesis, partly via improved renal cortical oxygenation as tubular glucose/sodium reabsorption work is reduced.

Mechanism

Named at the class level (Tier C for canagliflozin specifically): a mix of hemoconcentration from osmotic diuresis/mild volume contraction and genuinely enhanced erythropoiesis via increased erythropoietin synthesis, proposed to follow from reduced tubular workload and improved renal tissue oxygenation.

Counter-evidence held on record

This is a hematologic/oxygen-carrying capacity change, not an iron or B12 deficiency finding (see the separate Iron entry, which is unrelated and ungraded on its own drug-specific evidence). It is not evidence for or against iron supplementation. In patients already at risk of polycythemia, hematocrit should be monitored.

ATP production

Orange — Moderate

See study details

Canagliflozin shifts fuel metabolism toward fatty-acid oxidation and ketone body production; this is proposed as beneficial cardiac fuel supply in most patients but becomes dangerous (euglycemic diabetic ketoacidosis) in insulin-deficient, fasting, low-carbohydrate, or perioperative states.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real effect, but bounded by exposure window, subgroup, low frequency, or a functional (not deficiency-level) shift. orange

Limits on what this shows

  • Key negative/null findings: The case series is small (n=5) and does not establish population-level frequency of clinically important ketosis in stable, adequately insulinized type 2 diabetes patients on canagliflozin without other precipitants.
  • At-risk subgroups: Reduced insulin dose or omission, low-carbohydrate/ketogenic diets, prolonged fasting, surgery, acute illness, alcohol misuse, and off-label use in type 1 diabetes.
  • Counter-evidence on record: None found suggesting the fuel-shift mechanism is absent; the debate in the literature is about magnitude and risk context, not about whether it occurs.

Regulatory status

FDA label, Warnings and Precautions Section 5.1: "INVOKANA significantly increases the risk of diabetic ketoacidosis" in type 1 diabetes (an off-label population), and ketoacidosis "may be present even if blood glucose levels are less than 250 mg/dL"; fatal cases have been reported in the approved type 2 diabetes population as well.

Population evidence

Tier A regulatory-label confirmation that the fuel-shift mechanism is clinically significant. Drug-specific human corroboration: a small case series (5 patients with type 2 diabetes) reporting concomitant changes between ketone bodies and heart function with canagliflozin (Kutoh & Hayashi, Drug Research 2019).

Mechanism

Named, well-established for the SGLT2 inhibitor class: glucosuria-driven caloric loss and reduced insulin-to-glucagon ratio promote lipolysis, hepatic fatty-acid oxidation, and ketogenesis. In adequately insulinized patients this raises circulating ketones modestly; in insulin-deficient, fasting, low-carbohydrate-dieting, or acutely ill/perioperative patients it can progress to euglycemic diabetic ketoacidosis.

Counter-evidence held on record

This is a metabolic fuel shift, not a nutrient deficiency, and no supplement addresses it. The clinically important action is avoiding or managing the precipitants above and recognizing euglycemic DKA symptoms (nausea, vomiting, abdominal pain, malaise) even when blood glucose looks normal; the label advises holding canagliflozin before scheduled surgery and in acute illness.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Calcium

    Where it comes from: Plausible by analogy to loop and thiazide diuretics, which do alter urinary calcium handling, extrapolated to canagliflozin because it also causes osmotic diuresis and is sometimes informally grouped with "water pills" in depletion content.

    Why it fails: Directly contradicted by Tier A evidence: the 18-trial, 15,309-patient SGLT2 inhibitor meta-analysis (including canagliflozin-specific subgroups) found no significant change in serum calcium with treatment. Canagliflozin is pharmacologically distinct from loop/thiazide diuretics (it does not act on the loop of Henle or distal convoluted tubule sodium-chloride cotransporter), so the diuretic-class calcium-wasting mechanism does not apply.

All references used above
  1. FDA prescribing information (INVOKANA), label 204042s034lbl.pdf — Regulatory label. Pharmacokinetics, adverse reaction tables, bone fracture and ketoacidosis warnings. 2020 revision.
  2. DailyMed, INVOKANA (canagliflozin) tablet label, current SPL — Regulatory label, revised June 11, 2026. Boxed/warning sections for lower-limb amputation, bone fracture, genitourinary infections, ketoacidosis.
  3. Wang F, et al. Canagliflozin, serum magnesium and cardiovascular outcomes — analysis from the CANVAS Program. Endocrinol Diabetes Metab. 2021. — Post hoc analysis of pooled RCT data, N=10,140 (canagliflozin n=5,794, placebo n=4,346), type 2 diabetes, high cardiovascular risk. PMID 34277971.Direct WebFetch of this journal page returned a 403 error; data extracted via a secondary PMC-hosted copy of the same analysis (PMC8279612).
  4. de Jong MA, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia. 2016. DOI 10.1007/s00125-016-4101-6. — Meta-analysis, 18 RCTs, N=15,309, including canagliflozin, dapagliflozin, empagliflozin, ipragliflozin. Canagliflozin-specific dose-level subgroup data reported. PMID 27628105.
  5. Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, Bernstein S, Courville AB, Collins MT, Rother KI, Taylor SI. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight. 2018;3(8):e99123. DOI 10.1172/jci.insight.99123. — Randomized, single-blind, placebo-controlled crossover, NIH Clinical Center, N=25 healthy adults completed (29 randomized). Canagliflozin 300 mg/day x5 days. PMID 29669938.
  6. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH. J Clin Endocrinol Metab. 2024;109(2):e646. — Paired crossover study, Old Order Amish cohort, Lancaster PA, N=11 (25(OH)D ≤20 ng/mL at baseline), non-diabetic. Canagliflozin 300 mg/day x5 days, tested before and after vitamin D3 repletion.
  7. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016. DOI 10.1080/03007995.2016.1174841. PMID 27046479. — Analysis of canagliflozin Phase 3 program data, type 2 diabetes patients, 100 mg and 300 mg doses.Full text returned a 403 error on direct WebFetch; a companion source (PMID 27894216, below) supplied the quantitative bone data used in this dossier, and this citation is retained for the mineral-metabolism framing it establishes in secondary summaries reviewed.
  8. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. 2016. PMID 27894216. — Review/analysis of canagliflozin Phase 3 and CANVAS program bone data. 2-year total hip BMD: -1.7% (100 mg), -2.1% (300 mg) vs -0.8% (placebo). CANVAS fracture rate 1.6/100 patient-years (both doses) vs 1.1 (placebo). Beta-CTX and osteocalcin both increased.
  9. Packer M. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. Eur Heart J. 2023;44(48):5027-5033. — Narrative mechanistic review, no new primary data ("no new data were generated or analysed"). Discusses empagliflozin, dapagliflozin, ipragliflozin by name; canagliflozin confirmed absent from the discussion. Class-level/Tier C for canagliflozin.Canagliflozin not in scope of this specific review; used only for class-level mechanism context, not as canagliflozin-specific evidence.
  10. Bishr A, Atwa AM, El-Naggar ME, Nour El-Din M. Canagliflozin Promotes Mitochondrial Biogenesis in Glycerol-Induced Acute Kidney Injury by Activating the AMPK/SIRT1/FOXO-3a/PGC-1α and Nrf2/HO-1 Trajectories. 2021. DOI 10.2139/ssrn.3974361. — Animal (rat) acute kidney injury model.Indexed as an SSRN preprint at the time of this review; subsequent peer-reviewed journal publication was not independently confirmed.
  11. Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model. Sci Rep. 2020. DOI 10.1038/s41598-020-71599-2. — Animal model, canagliflozin-specific.
  12. Effect of Canagliflozin on the crosstalk between ER Stress and Oxidative stress in Diabetic Nephropathy: A Role of Nrf2. Diabetes Res Clin Pract. 2023. DOI 10.1016/j.diabres.2023.110408. — Animal/in vitro diabetic nephropathy model, canagliflozin-specific.
  13. Role of canagliflozin in ameliorating isoprenaline induced cardiomyocyte oxidative stress via the heme oxygenase-1 mediated pathway. Biotechnic & Histochemistry. 2023. DOI 10.1080/10520295.2023.2262390. — Animal/in vitro cardiomyocyte model, canagliflozin-specific.
  14. Canagliflozin Alleviates Atherosclerosis Progression through Inflammation, Oxidative Stress, and Autophagy. Cardiovasc Innov Appl. 2024. DOI 10.15212/cvia.2023.0093. — Animal model, canagliflozin-specific.
  15. Schiattarella GG, Bode D. Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage. Eur Heart J. 2021;42(48):4961-4963. DOI 10.1093/eurheartj/ehab519. — Editorial/commentary, canagliflozin-specific mechanistic caution regarding off-target SGLT1 inhibition in myocardium. The primary study this editorial comments on could not be retrieved in this review.
  16. The effect of canagliflozin on gut microbiota and metabolites in type 2 diabetic mice. Genes Genomics. 2024. DOI 10.1007/s13258-024-01491-0. — Mouse model, type 2 diabetic mice, 8-week gavage, canagliflozin-specific.
  17. Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus. 2023. PMID 37867512. — Human, type 2 diabetes cohort, canagliflozin-specific, per title/indexing.Full text/abstract could not be extracted: PubMed's article page returned only an empty JavaScript shell to the fetch tool, and PMC/Europe PMC access was repeatedly rate-limited (429) or connection-rejected (403) throughout this session. Quantitative results (taxa, effect sizes) are not independently confirmed in this dossier; only the drug/population/finding-direction implied by the title is used.
  18. Docherty KF. SGLT2 Inhibitors and Iron. JACC Heart Fail. 2023. DOI 10.1016/j.jchf.2023.08.013. — Commentary referencing DAPA-HF, EMPA-REG OUTCOME, and EMPEROR-Reduced trial data (dapagliflozin, empagliflozin). Canagliflozin confirmed absent from cohort.Canagliflozin not in the studied cohorts referenced; used only for class-level extrapolation, graded no higher than yellow.
  19. Kutoh E, Hayashi J. Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes. Drug Res (Stuttg). 2019. DOI 10.1055/a-0748-5745. — Case series, N=5, type 2 diabetes, canagliflozin-specific.
  20. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: A10BK02 (canagliflozin). — Reference index. DDD 0.2 g, oral.
  21. Crossref API search results (canagliflozin + iron/ferritin; canagliflozin + copper). — Used as negative-evidence documentation for the Iron and Copper entries: no canagliflozin-specific results returned for either query after review of all items returned.